State Key Laboratory of Chemical Engineering, Center for Chemistry of High-Performance & Novel Materials, Department of Chemistry, Zhejiang University, Hangzhou 310027, P. R. China.
Chem Soc Rev. 2021 Feb 21;50(4):2839-2891. doi: 10.1039/d0cs00011f. Epub 2021 Feb 1.
Among the many challenges in medicine, the treatment and cure of cancer remains an outstanding goal given the complexity and diversity of the disease. Nanotheranostics, the integration of therapy and diagnosis in nanoformulations, is the next generation of personalized medicine to meet the challenges in precise cancer diagnosis, rational management and effective therapy, aiming to significantly increase the survival rate and improve the life quality of cancer patients. Different from most conventional platforms with unsatisfactory theranostic capabilities, supramolecular cancer nanotheranostics have unparalleled advantages in early-stage diagnosis and personal therapy, showing promising potential in clinical translations and applications. In this review, we summarize the progress of supramolecular cancer nanotheranostics and provide guidance for designing new targeted supramolecular theranostic agents. Based on extensive state-of-the-art research, our review will provide the existing and new researchers a foundation from which to advance supramolecular cancer nanotheranostics and promote translationally clinical applications.
在医学领域的众多挑战中,由于癌症的复杂性和多样性,癌症的治疗和治愈仍然是一个突出的目标。纳米诊疗一体化是将治疗和诊断集成在纳米制剂中的新一代个性化药物,旨在满足精确癌症诊断、合理管理和有效治疗的挑战,旨在显著提高癌症患者的生存率和生活质量。与大多数传统平台的治疗效果不理想不同,超分子癌症纳米诊疗具有在早期诊断和个体化治疗方面无与伦比的优势,在临床转化和应用方面显示出巨大的潜力。在这篇综述中,我们总结了超分子癌症纳米诊疗的进展,并为设计新的靶向超分子治疗剂提供了指导。基于广泛的最新研究,我们的综述将为现有和新的研究人员提供一个基础,以推进超分子癌症纳米诊疗,并促进其向临床应用的转化。